Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Keywords:
Large B-cell lymphoma
SADAL
B-cell tumour
Cytogenetics
DLBCL
Editorial note:
© 2020 Elsevier Ltd. All rights reserved.
Citation:
Canales-Albendea, M. A. (Miguel Ángel); Kalakonda, N. (Nagesh); Maerevoet, M. (Marie); et al. "Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial". The Lancet. Haematology. 7 (7), 2020, e511 - e522
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.